CN113440601B - Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma - Google Patents
Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma Download PDFInfo
- Publication number
- CN113440601B CN113440601B CN202110182314.8A CN202110182314A CN113440601B CN 113440601 B CN113440601 B CN 113440601B CN 202110182314 A CN202110182314 A CN 202110182314A CN 113440601 B CN113440601 B CN 113440601B
- Authority
- CN
- China
- Prior art keywords
- nasopharyngeal carcinoma
- tfpi
- cells
- cell
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010061306 Nasopharyngeal cancer Diseases 0.000 title claims abstract description 66
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 63
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 title claims abstract description 62
- 201000011216 nasopharynx carcinoma Diseases 0.000 title claims abstract description 62
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title claims abstract description 48
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 6
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 9
- 238000002054 transplantation Methods 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010034023 Parotid gland enlargement Diseases 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010068548 Soft tissue atrophy Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 101710139626 Tissue factor pathway inhibitor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention provides an application of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma. The invention discovers for the first time that a Tissue Factor Pathway Inhibitor (TFPI) is used as a synergist of a natural killer cell (NK cell) for resisting nasopharyngeal carcinoma, can promote the NK cell to inhibit the growth of nasopharyngeal carcinoma cell transplantation tumor, and obviously improves the curative effect of the NK cell in the aspect of preventing and treating the nasopharyngeal carcinoma, so that the tissue factor pathway inhibitor and the TFPI are combined to play a role of synergy, thereby not only providing new application of the NK cell and the TFPI, but also providing a new treatment medication scheme for treating the nasopharyngeal carcinoma, and having extremely high market value in the aspect of preventing and treating the nasopharyngeal carcinoma.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an application of NK cells and TFPI in prevention and treatment of nasopharyngeal carcinoma.
Background
Nasopharyngeal carcinoma is one of malignant tumors in China, the incidence rate is the first of the malignant tumors of ear, nose and throat, most of the nasopharyngeal carcinoma has moderate sensitivity to radiotherapy, so the radiotherapy is the first choice for treating the nasopharyngeal carcinoma, but the radiotherapy may generate a plurality of complications: 1) systemic reaction: including weakness, dizziness, impaired appetite, nausea, vomiting, tastelessness or taste deterioration in the mouth, insomnia or lethargy, etc., individual patients may even have hemogram changes, especially with reduced white blood cell count; 2) local reaction: the method comprises the reactions of skin, mucous membrane and salivary gland, wherein the skin reaction is dry dermatitis or even wet dermatitis, the mucous membrane reaction is nasopharynx and oropharynx mucous membrane congestion, edema, exudation, secretion accumulation and the like, the salivary gland reaction is characterized in that parotid swelling occurs when a small number of patients irradiate parotid gland with 2Gy, the salivary secretion is obviously reduced when the patients irradiate with 40Gy, and the parotid swelling is accompanied with the increase of oral mucous membrane secretion, the congestion and swelling of mucous membrane, the dry mouth of the patients, the difficulty in dry eating and the like; 3) and (3) postradiotherapy withdrawal symptoms: mainly comprises temporomandibular joint dysfunction, soft tissue atrophy and fibrosis, radioactive decayed teeth, radioactive osteomyelitis of jaw and radioactive encephalomyelitis, and at present, no adequate method for reversion exists. In addition, most patients are in the middle and late stage at clinic, and for cases with low differentiation of cancer, late course of disease and recurrence after radiotherapy, the recurrence and metastasis of nasopharyngeal carcinoma still occur frequently although they are treated by normal means such as surgery, radiotherapy and chemotherapy.
The immune cell therapy is the fourth method for treating tumors after operations, chemotherapy and radiotherapy, and has the advantages of strong specificity, light side effect and the like, so that the method for screening and improving the anti-tumor capability of the immune cells becomes one of the current anti-tumor research hotspots. Natural killer cells (NK) are one of the important immune cells in the body, and are associated with anti-tumor, anti-viral infection and immune regulation, but have limited anti-tumor effects according to practical effects. In the prior art, the anti-tumor capability of an NK cell is improved from the genome of the NK cell, for example, patent CN201610445517.0 provides an NK cell which can express an antibody efficiently and stably, an expression frame containing a coding sequence of an antibody of a human Fc region is stably integrated in the genome of the NK cell, and both ends of the expression frame contain inverted terminal repeat sequences of transposons, so that anti-tumor cellular immunity and humoral immunity can be exerted at the same time, and proliferation of tumor and virus is effectively inhibited.
However, the research aiming at improving the anti-tumor ability of NK cells is less, so that a new method for improving the ability of NK cells to kill nasopharyngeal carcinoma tumor cells needs to be developed urgently.
Disclosure of Invention
The invention aims to solve the defects of the existing NK cell in the aspect of tumor resistance and provides an application of the NK cell and TFPI in preventing and treating nasopharyngeal carcinoma. The invention discovers for the first time that a Tissue Factor Pathway Inhibitor (TFPI) serving as a synergist of natural killer cells (NK cells) for resisting nasopharyngeal carcinoma can promote the growth inhibition of the NK cells on nasopharyngeal carcinoma cell transplantable tumors and obviously improve the curative effect of the NK cells on the prevention and treatment of the nasopharyngeal carcinoma, so that the tissue factor pathway inhibitor and the synergist are combined to play a role in synergy.
Therefore, it is an object of the present invention to claim the use of TFPI as a potentiator of NK cells against nasopharyngeal carcinoma.
It is a further object of the present invention to claim the use of NK cells in combination with TFPI in the preparation of a medicament for the treatment of nasopharyngeal carcinoma.
The invention also aims to provide a medicament for treating nasopharyngeal carcinoma.
The above purpose of the invention is realized by the following technical scheme:
the invention requests to protect the application of TFPI in serving as a synergist of NK cells for resisting nasopharyngeal carcinoma, and requests to protect the application of the NK cells and the TFPI in preparing medicines for resisting the nasopharyngeal carcinoma.
NK cells are a type of lymphocyte of human peripheral blood; TFPI is an in vivo native anticoagulant protein that controls the initiation phase of coagulation, has specific inhibitory effects on the Tissue Factor (TF) pathway (i.e., extrinsic coagulation pathway), and has been referred to as an extrinsic pathway inhibitor. The invention discovers for the first time that TFPI serving as a synergist of NK cells for resisting nasopharyngeal carcinoma can promote the growth inhibition of NK cells on nasopharyngeal carcinoma cell transplantation tumor and obviously improve the curative effect of the NK cells on the prevention and treatment of the nasopharyngeal carcinoma, so that the invention combines the NK cells and the TFPI to play a role of synergy of the NK cells and the TFPI, thereby not only providing new application of the NK cells and the TFPI, but also providing a new treatment medication scheme for the treatment of the nasopharyngeal carcinoma, and having extremely high market value on the prevention and treatment of the nasopharyngeal carcinoma.
Preferably, the anti-nasopharyngeal cancer comprises inhibiting growth of nasopharyngeal cancer.
More preferably, said inhibiting the growth of nasopharyngeal carcinoma comprises inhibiting the growth of nasopharyngeal carcinoma cells.
Most preferably, said inhibiting the growth of nasopharyngeal carcinoma cells comprises inhibiting the growth of a nasopharyngeal carcinoma cell transplant tumor.
Preferably, the nasopharyngeal carcinoma comprises EBV-positive nasopharyngeal carcinoma.
The invention also provides a medicine for treating nasopharyngeal carcinoma, which comprises NK cells and TFPI.
Preferably, the medicament further comprises a medically acceptable adjuvant or carrier.
Preferably, the medicament is in the form of injection, oral liquid or suspension.
The invention has the following beneficial effects:
the invention discovers for the first time that TFPI as a synergist of NK cells for resisting nasopharyngeal carcinoma can promote the growth inhibition of NK cells on nasopharyngeal carcinoma cell transplantation tumor and obviously improve the curative effect of the NK cells in preventing and treating the nasopharyngeal carcinoma, so that the invention combines the NK cells and the TFPI to play a role of synergy of the NK cells and the TFPI, not only provides new application of the NK cells and the TFPI, but also provides a new treatment medication scheme for treating the nasopharyngeal carcinoma, and has extremely high market value in preventing and treating the nasopharyngeal carcinoma.
Drawings
FIG. 1A is a graph of tumor volume; FIG. 1B is a graph of tumor size change; fig. 1C is a bar graph of tumor weight changes.
FIG. 2A shows immunohistochemical results; FIG. 2B shows the results of flow cytometry.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Years of practical research work of the inventor shows that more than 98% of patients with nasopharyngeal carcinoma are EBV positive nasopharyngeal carcinoma clinically, so the EBV positive nasopharyngeal carcinoma is taken as an example in the embodiment of the invention.
Example 1
First, experimental material
1. Tissue Factor Pathway Inhibitor (TFPI): purchasing in market;
2. natural killer cells (NK cells): NK cells of human umbilical cord blood;
3. cancer cell: EBV positive nasopharyngeal carcinoma cells (HK 1-EBV);
4. immunodeficient NCG mice: is commercially available.
Second, grouping experiments
1. Blank control group: EBV positive nasopharyngeal carcinoma cells were not treated with any drug.
2. TFPI group: EBV-positive nasopharyngeal cancer cells were treated with TFPI.
3. NK cell group: EBV positive nasopharyngeal cancer cells were treated with NK cells.
4. NK cells + TFPI group: EBV-positive nasopharyngeal carcinoma cells were treated simultaneously with NK cells and TFPI.
Third, experiment of subcutaneous tumor formation in immunodeficient NCG mice
1. Respectively mixing 5 × 106Individual EBV-positive nasopharyngeal carcinoma cells (HK1-EBV) were implanted subcutaneously in the axilla of 20 4-week-old immunodeficient NCG mice, and were randomly and evenly divided into 4 groups: blank control group, TFPI group, NK cell + TFPI group.
2. When the subcutaneous tumor volume reaches 100-200 mm3Three experimental groups were treated in the following manner:
(1) TFPI group: TFPI was administered at 0.66 mg/kg/mouse tumor 1 time per day.
(2) NK cell group: day 1 tail vein administration of 1 NK cells 1.5X 107One IL-15(10 ng/one/day) was administered intraperitoneally on days 2-8, and 1 IL-2(10 ng/one/day) was administered intraperitoneally on days 1-214Unit/only/2 days).
(3) NK cells + TFPI group: TFPI was administered at 0.66 mg/kg/mouse tumor 1 time per day; day 1 tail vein administration of 1 NK cells 1.5X 107One/one, 1 intraperitoneal administration of IL-15(10 ng/one) on days 2-8Day), 1-21 days of intraperitoneal administration of 1 time of IL-2 (10)4Unit/only/2 days).
3. Tumor volume was measured every two days (FIG. 1A), mice were sacrificed by cervical dislocation after four weeks, tumor tissue was excised, analyzed for size (FIG. 1B), weight (FIG. 1C), and tumor differences between groups were compared.
4. Immunohistochemistry examined the expression of platelet markers (CD41, fig. 2A) and flow cytometry examined the expression of NK cell markers (CD45, CD56, NKG2D and CD69) (fig. 2B) in tumor tissues.
Fourth, results and analysis
As can be seen from fig. 1, the NK cell group has a very small inhibitory effect on the growth of the EBV-positive nasopharyngeal carcinoma cell transplantation tumor, the TFPI group has a certain inhibitory effect on the growth of the EBV-positive nasopharyngeal carcinoma cell transplantation tumor, and the NK cell group and the TFPI group have a significant inhibitory effect on the growth of the EBV-positive nasopharyngeal carcinoma cell transplantation tumor, indicating that the two are used together to exert a synergistic anti-tumor effect, the TFPI promotes the inhibition of the NK cell on the growth of the nasopharyngeal carcinoma cell transplantation tumor, significantly improves the curative effect of the NK cell on the prevention and treatment of the nasopharyngeal carcinoma, provides a new therapeutic drug regimen for the treatment of the nasopharyngeal carcinoma, and has a very high market value in the prevention and treatment of the nasopharyngeal carcinoma.
As can be seen in fig. 2A, TFPI primarily inhibits CD41 platelet formation in tumor tissue; as shown in FIG. 2B, the combination of NK cells and TFPI can enhance the activity of NK cells and slow down the formation of transplanted tumors, and the combination of NK cells and TFPI does not have the negative effects of mutual inhibition and the like.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (5)
- Application of TFPI in preparation of synergist of human umbilical cord blood NK cell medicine for resisting EB virus positive nasopharyngeal carcinoma is disclosed.
- 2. The human umbilical cord blood NK cell and TFPI are combined to be used for preparing the medicine for resisting EB virus positive nasopharyngeal carcinoma.
- 3. The use of claim 1 or 2, wherein said anti-epstein-barr virus positive nasopharyngeal carcinoma comprises inhibiting growth of epstein-barr virus positive nasopharyngeal carcinoma.
- 4. The use of claim 3, wherein said inhibiting the growth of Epstein-Barr virus positive nasopharyngeal carcinoma comprises inhibiting the growth of Epstein-Barr virus positive nasopharyngeal carcinoma cells.
- 5. The use of claim 4, wherein said inhibiting the growth of EB virus positive nasopharyngeal carcinoma cells comprises inhibiting the growth of EB virus positive nasopharyngeal carcinoma cell transplantable tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110182314.8A CN113440601B (en) | 2021-02-08 | 2021-02-08 | Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110182314.8A CN113440601B (en) | 2021-02-08 | 2021-02-08 | Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113440601A CN113440601A (en) | 2021-09-28 |
| CN113440601B true CN113440601B (en) | 2022-01-21 |
Family
ID=77808810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110182314.8A Active CN113440601B (en) | 2021-02-08 | 2021-02-08 | Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113440601B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586016B1 (en) * | 2001-09-13 | 2003-07-01 | Sagittarius Life Science Corp. | ST 188L as the prevention and treatment for cancers and infections |
| CN107523546A (en) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | A kind of NK cells of high efficiency stable expression antibody and application thereof |
| CN110357962A (en) * | 2018-07-06 | 2019-10-22 | 北京天成新脉生物技术有限公司 | Low ADCC/CDC Functional antibody and the preparation method and application thereof |
| CN111041064A (en) * | 2019-07-22 | 2020-04-21 | 徐州医科大学 | Method for evaluating CAR-T killing activity in vitro |
| CN111910000A (en) * | 2020-07-02 | 2020-11-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis |
| CN112225812A (en) * | 2015-02-25 | 2021-01-15 | 财团法人牧岩生命科学研究所 | Novel antibodies that bind TFPI and compositions comprising the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3606518A4 (en) * | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
-
2021
- 2021-02-08 CN CN202110182314.8A patent/CN113440601B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586016B1 (en) * | 2001-09-13 | 2003-07-01 | Sagittarius Life Science Corp. | ST 188L as the prevention and treatment for cancers and infections |
| CN112225812A (en) * | 2015-02-25 | 2021-01-15 | 财团法人牧岩生命科学研究所 | Novel antibodies that bind TFPI and compositions comprising the same |
| CN107523546A (en) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | A kind of NK cells of high efficiency stable expression antibody and application thereof |
| CN110357962A (en) * | 2018-07-06 | 2019-10-22 | 北京天成新脉生物技术有限公司 | Low ADCC/CDC Functional antibody and the preparation method and application thereof |
| CN111041064A (en) * | 2019-07-22 | 2020-04-21 | 徐州医科大学 | Method for evaluating CAR-T killing activity in vitro |
| CN111910000A (en) * | 2020-07-02 | 2020-11-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Tumor microenvironment component marker combination and system for predicting nasopharyngeal carcinoma prognosis |
Non-Patent Citations (2)
| Title |
|---|
| "TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin";Debra A.Hoppensteadt等;《Thrombosis Research》;19950131;第77卷(第2期);第175-185页 * |
| Tissue Factor Pathway Inhibitor Gene Polymorphism −33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer;A.K.Bazzarellli MD等;《Annals of Surgical Oncology》;20160311;第23卷;第2277-2278页DISSCUSSION讨论部分第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113440601A (en) | 2021-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marquet et al. | Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site | |
| JP2813017B2 (en) | How to reduce side effects of cancer therapy | |
| US5601818A (en) | Cancer therapy utilizing malignant cells expressing HSV-TK | |
| US5128126A (en) | Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions | |
| CN114870009A (en) | Anti-tumor combined composition, application thereof and anti-tumor medicine | |
| CN113599527B (en) | Application of APOE inhibitor and PD-1 monoclonal antibody in preparation of medicine for treating digestive tract tumor | |
| Nobin et al. | Interferon treatment in patients with malignant carcinoids | |
| CN113440601B (en) | Application of combination of NK cells and TFPI in preventing and treating nasopharyngeal carcinoma | |
| JPH0723309B2 (en) | Cancer treatment | |
| EA028081B1 (en) | Composition for treating prostate cancer, method for treating an individual having prostate cancer and method for inducing an immunotherapeutic response in the same | |
| CN114452391B (en) | Application of CDK16 as target in preparation of medicine for treating triple negative breast cancer | |
| CN106540253A (en) | The application of cGAMP and its derivant in anti-tumor vaccine is prepared | |
| JPH05508769A (en) | β-Aretin useful for cell culture and therapy | |
| TW201808316A (en) | Use of compositions of water/alcohol extracts of Antrodia cinnamomea cut-log cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| CN114712393B (en) | Application of Hnf-1 alpha gene modified mesenchymal stem cells in preventing and treating liver cancer | |
| Collins et al. | Reversal of gold-induced neutropenia with granulocyte colony-stimulating factor (G-CSF) | |
| WO2019149039A1 (en) | Antitumor protein composition and application thereof | |
| CN101074266A (en) | Transduced peptide-humanized granular leukocyte colony stimulating factor fusion protein and its medicinal composition | |
| Yefenof et al. | Suppressor and reactive lymphocytes in radiation leukemia virus (RadLV)-induced leukemogenesis | |
| RU7872U1 (en) | PREPARATION "BETALEYKIN" | |
| CN107929344B (en) | Lithospermum compound composition for preventing and treating laryngeal cancer | |
| CN109419795B (en) | Combined medicine for treating tumor necrosis factor family related diseases | |
| Bschor et al. | The use of lithium in non-psychiatric conditions | |
| CN114848681A (en) | Immunotherapy composition and application thereof | |
| CN114632088A (en) | Application of cytarabine compound in preparation of medicine for treating glioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220802 Address after: 510700 room B016, floor 5, No. 848, Maogang Road, Huangpu District, Guangzhou City, Guangdong Province Patentee after: Guangzhou exes Biomedical Technology Co.,Ltd. Address before: No.135, Xingang West Road, Haizhu District, Guangzhou City, Guangdong Province Patentee before: SUN YAT-SEN University Patentee before: SUN YAT SEN University CANCER CENTER (SUN YAT SEN University AFFILIATED TO CANCER CENTER SUN YAT SEN UNIVERSITY CANCER INSTITUTE) |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240226 Address after: Building C3, 7th Floor, No. 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province, 510535 Patentee after: Guangzhou Zhongxin gene Medical Technology Co.,Ltd. Country or region after: China Address before: 510700 room B016, floor 5, No. 848, Maogang Road, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangzhou exes Biomedical Technology Co.,Ltd. Country or region before: China |